Dan Paterson, Verastem Oncology CEO
Verastem Oncology secures collaboration with GenFleet Therapeutics, potentially worth up to $600M+
Verastem Oncology inked a deal potentially worth up to $625.5 million with Chinese biotech GenFleet Therapeutics that aims to move three oncology programs into the clinic.
Verastem will pay GenFleet $11.5 million for one program, though the deal size for all three programs is worth up to $625.5 million, excluding royalties. The deal will also give GenFleet the development and commercial rights to those three candidates in China, while Verastem would get the rights for the drugs everywhere else.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
